At Anthropic’s June 30 event in San Francisco called “The Briefing: AI for Science,” CEO Dario Amodei did not declare that AI’s impact on biology had unleashed the “compressed 21st century” effect he described in his October 2024 essay, instead emphasizing he does not expect it to transpire in the next couple of years and floated that it “might” happen a decade from now. The company unveiled Claude Science, a new version of Claude tuned for scientific research launching in beta today, with a demo by Alexander Tarashansky showing a chatbot feel with richer tools for finding and manipulating information. Panel discussions included Amodei, GLP-1 drug inventor Lotte Knudsen, Bristol Myers Squibb CEO Chris Boerner, Novartis CEO Vas Narasimhan, and Genentech executive VP Aviv Regev, with conversations acknowledging that even rapidly improving AI can do only so much to advance fields such as drug discovery.